1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
暂无分享，去创建一个
G. Lyon | B. Alexander | F. Marty | M. Hoenigl | R. Krause | D. Andes | T. Patterson | L. Ostrosky-Zeichner | P. Pappas | O. Cornely | J. Sanders | C. Morse | A. Spec | N. Azie | R. Rautemaa‐Richardson | M. Miceli | D. Angulo | R. Miller | G. Thompson | J. Vázquez | Emily A. Silverman